Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance
Authors:
Open Access
- 11 January 2022
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (1) , e2142703
Abstract
Approximately 15% of patients with ovarian cancer have a germline BRCA (gBRCA) variation,1 which has important implications, including increased sensitivity to platinum-based chemotherapy and poly(ADP-ribose) polymerase inhibitors and improved survival.2 Testing first-degree relatives is also cost-effective cancer prevention.3 Since 2010, guidelines have recommended universal testing in ovarian cancer. However, testing rates are reportedly between 10% and 30%,4 and few studies have examined commercially insured populations or identified patient-, physician-, and practice-level characteristics associated with testing rates.Keywords
This publication has 6 references indexed in Scilit:
- Multimodality Cancer Care and Implications for Episode-Based Payments in Cancer2019
- Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer PatientsJournal of Clinical Oncology, 2019
- Inherited Mutations in Women With Ovarian CarcinomaJAMA Oncology, 2016
- Utilization and Outcomes ofBRCAGenetic Testing and Counseling in a National Commercially Insured PopulationJAMA Oncology, 2015
- Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian CancerJAMA, 2011
- Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation CarriersJNCI: Journal of the National Cancer Institute, 2009